Ramona Sequeira
Ramona Sequeira has over 30 years of experience in the biopharmaceutical industry across multiple geographies and healthcare systems globally. Ms. Sequeira spent 10 years at Takeda Pharmaceutical Company, serving first as President, Takeda Pharmaceuticals USA. During this time, she oversaw a three-fold expansion of Takeda’s US business through organic and in-organic growth, contributing over half of the company’s global revenue. She initiated the building of key capabilities including data and analytics, medical affairs, access and reimbursement and corporate affairs to enable sustainable patient access to Takeda’s medicines. Subsequently, as President of Takeda’s newly created Global Portfolio Division, she oversaw the company’s Vaccines business unit in addition to global markets including Europe, Growth and Emerging Markets and China. She played a pivotal role in Takeda’s approval and launch of a vaccine for Dengue fever and Takeda’s first global vaccine, launched into travel and endemic markets around the world.
As leader of Takeda’s Global Commercial and Global Medical organizations, Ms. Sequeira also co-chaired Takeda’s pipeline review committee and oversaw the development of launch strategies for pipeline assets.
Prior to Takeda, Ms. Sequeira spent 20 years at Eli Lilly and Company in various leadership roles in Canada, Europe and the US, during which time she launched numerous brands in the Neuroscience therapy area.
Ms. Sequeira also served on the PhRMA board of directors for seven years. During her tenure, she served as Treasurer, Vice-Chair, and Chair, the first woman to do so in PhRMA’s history.
Ms. Sequeira currently also serves as a member of the board of directors of Edwards Lifesciences Corporation, a medical technology company specialized in structural heart disease.
Ms. Sequeira received her M.B.A. from McMaster University and an Honours Bachelor of Science degree in molecular genetics and molecular biology from the University of Toronto.
